David Feltquate, Ph.D, MD

Chief Medical Officer

Dr. Feltquate's Oncology and Drug Development career spans over 25 years. He most recently served as CMO at iTeos Therapeutics and previously held the same role at Palleon Pharmaceuticals. Earlier in his career, he was the Global Head of Hematology Development and Chair of the Precision Medicine Leadership Team at Novartis. Before this, he held numerous leadership positions at BMS including Head of Oncology Early Clinical Development and Development Leader for Ipilimumab/Nivolumab Life Cycle Management. As the Nivolumab Clinical Head, he was responsible for the clinical development of the first PD-1 inhibitor from proof of concept through initial registration in NSCLC, Melanoma, and RCC. He is also currently a non-Executive Board Member at Nerviano Medical Sciences – US and an SAB member of Telperian, Onc.AI, and Numenos AI. He earned a BS in biology from MIT and an MD/PhD in Immunology from the University of Massachusetts Medical School. He completed Internal Medicine training and was Chief Resident at Dartmouth Hitchcock Medical Center and Medical Oncology training at the Memorial Sloan-Kettering Cancer Center.